CD34 and neoplasm: One of the potential sources to accomplish clinically relevant doses of tumor-reactive NK cells is making use of HSC (CD34+) through differentiation and expansion of CD34+ cells isolated from bone marrow, peripheral blood, or UCB into functional NK cells.